LATEST
外 Waitan Ludi Policy Terminal China industrial-policy monitor · updated 2026-10-25
view asAnalystMonitorPolicymakerBusinessLegal
← Documents · Graph

关于印发《奉贤区促进生物医药产业高质量发展若干政策》的通知

Notice on the Issuance of the ‘Several Policies of Fengxian District to Promote the High-Quality Development of the Biopharmaceutical Industry’
奉科〔2025〕15号
Radar: Pharmaceuticals (rank 4 of 16)

Country-interest evidence · pilot

Trade inferences use UN Comtrade, with China as reporter. Country connections indicate potential trade relevance, not measured harm, firm-level exposure or legal applicability. Inward measures concern exporters to China; competition with Chinese exports in third markets is not assessed.

Inspect implementing jurisdictions and partner evidence · 47 relationships

Argentina: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 66,684,030

Australia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 245,746,625

Austria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 874,496,180

Belgium: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 967,285,048

Bulgaria: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 4,541,275

Brazil: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 17,310,789

Canada: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 322,497,907

Switzerland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 3,215,037,262

Cuba: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 1,462,576

Cyprus: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 2,593,380

Germany: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 6,283,351,582

Denmark: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 1,352,519,126

Spain: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 810,956,304

Finland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 186,906,389

France: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 3,172,042,789

United Kingdom: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 967,855,251

Greece: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 295,040,229

Hong Kong, China: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 629,258,838

Croatia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 2,826,627

Hungary: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 50,167,052

Indonesia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 3,885,578

India: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 134,981,359

Ireland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 7,017,178,653

Israel: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 52,572,750

Italy: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 3,146,018,573

Japan: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 1,993,853,072

Korea, Rep.: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 91,477,194

Lithuania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 4,009,008

Macao: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 1,143,254

Mexico: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 2,136,628

Netherlands: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 685,464,233

Norway: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 22,348,736

New Zealand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 44,929,201

Poland: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 35,898,226

Portugal: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 7,521,807

Romania: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 17,489,565

Russian Federation: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 1,067,002

Singapore: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 161,047,405

Slovenia: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 18,048,490

Sweden: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 1,726,946,564

Thailand: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 16,745,470

Turkey: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 10,008,462

Chinese Taipei: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 173,380,294

Uruguay: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 15,123,065

United States: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 5,866,439,352

South Africa: Trade-based inference; exporters to China; summed product trade > USD 1m; 2024 trade; broad sector headings; computed, not analyst-reviewed · intervention 61962 · recorded trade USD 18,828,992

Implementing jurisdiction: China · intervention 61962

Assessment states
  • Trade-based partners recorded

Measures

Capital grant
County · origin: Chinese firms or production in China · locality: Local firms · CPC 352 · in force from 2025-08-04 · until 2027-12-31 · Keyword screen (unreviewed)
Implemented by China (subnational) · affects 46 partners (inferred from trade data, 2024 trade): Ireland, Germany, United States, Switzerland, France, Italy …
支持生物医药产业领域新建和改扩建高端项目建设，单个项目给予最高3000万元的前期费奖励，或按照不超过项目固定资产投资总额的10%，给予单个项目最高5000万元的建设费奖励。
Supports production in a place, so favours that place by rule.

Asymmetric provisions

Ownership, own-brand or own-IP test (自主品牌, 自主知识产权, 股比)
Disadvantages: foreign-owned firms · Keyword screen (unreviewed)
对具有自主知识产权并取得其他第二类(不含第二类诊断试剂及设备零部件)、第三类医疗器械注册证并落地生产的，按照不超过产品研发费用的20%，分别给予最高50万元、100万元支持。
Ownership, own-brand or own-IP test (自主品牌, 自主知识产权, 股比)
Disadvantages: foreign-owned firms · Keyword screen (unreviewed)
支持原料药及关键中间体研发与产业化，对具有自主知识产权或突破性工艺并投产的高端原料药及高附加值医药中间体，按照不超过产品研发费用的20%，给予最高100万元支持。
SOE or private-firm preference (国有企业, 民营企业)
Disadvantages: · Keyword screen (unreviewed)
扶持资金由区、街镇(开发区及国企)按财力结算比例分别承担。

Full text

印发日期：2025-08-04奉科〔2025〕15号 各相关单位： 现将《奉贤区促进生物医药产业高质量发展若干政策》印发给你们，请遵照执行。 特此通知。 附件：《奉贤区促进生物医药产业高质量发展若干政策》 上海市奉贤区科学技术委员会 上海市奉贤区财政局 2025年7月29日 附件： 奉贤区促进生物医药产业高质量发展若干政策 为贯彻落实《关于支持生物医药产业全链条创新发展的若干意见》(沪府办规〔2024〕9号)文件精神，加快优化奉贤区生物医药产业创新和发展环境，提升产业综合竞争力，特制定本政策。 一、支持对象 依法从事药品、医疗器械(包含诊断试剂)等生物医药产业领域的研发、生产、销售和服务的企事业单位或民办非企业单位。 二、支持内容 (一)支持项目建设 1.支持重大项目建设。支持生物医药产业领域新建和改扩建高端项目建设，单个项目给予最高3000万元的前期费奖励，或按照不超过项目固定资产投资总额的10%，给予单个项目最高5000万元的建设费奖励。 2.支持产业平台建设。加快培育优质生物医药产业平台，鼓励第三方检测和认证服务、共性实验室、实验动物服务、药物筛选、药理毒理研究、成效性评价、孵化转化、新药报批等公共服务平台及通用技术平台建设，按照不超过实际投入的30%，给予单个项目最高1000万元支持。重点支持填补产业链空白的专业平台建设，单个项目最高1500万元。为加快推进细分赛道专业园区建设，对生态体系完善、运营成效显著的园区，给予最高1000万元支持。 (二)支持研发创新 3.支持核心技术攻关。支持生物医药领域基础理论创新和前沿技术发展，聚焦细胞与基因治疗、mRNA、合成生物、再生医学和医疗器械核心部件攻关等领域进行技术突破。支持人工智能技术在研发和生产中的应用，开展示范智能化应用场景。支持生物技术在食品、化妆品、农业和材料等领域跨界融合。对开展关键核心技术攻关，推动颠覆性、通用技术、前沿技术突破项目，按照不超过项目研发费用的30%，给予单个项目最高200万元支持。 4.支持新药研发和转化。对1类化学药、中药、生物制品，进入国内外临床试验，给予最高100万元支持;对完成Ⅰ、Ⅱ、Ⅲ期国内临床试验，对不同阶段给予不超过产品研发费用的30%，分别给予最高200万元、400万元、800万元支持;对完成Ⅰ、Ⅱ、Ⅲ期海外临床试验，按照规定给予最高分别100万元、200万元、300万元支持。对其中仅需完成国内早期临床试验、确证性临床试验的细胞与基因治疗1类新药，按照规定对完成不同阶段临床试验给予不超过产品研发费用的30%，最高分别500万元、800万元支持;对完成海外临床试验，按照规定对不同阶段给予最高分别200万元、300万元支持。 对2类化学药、中药、生物制品，进入国内临床试验，给予最高50万元支持;对完成Ⅰ、Ⅱ、Ⅲ期国内临床试验，按照不超过产品研发费用的20%，分别给予最高50万元、100万元、200万元支持。 对经典名方中药复方制剂完成研发，按照不超过产品研发费用的20%，给予最高50万元支持。 对上述获得药品注册证书并实现生产，或成为上市许可持有人并落地生产的，对1、2类新药和经典名方，按照不超过产品研发费用的30%，分别给予最高1000万元、200万元、100万元支持。 对取得兽药注册证并自主实施产业化(或委托生产)的第一类、第二类产品(不含兽医诊断制品)，分别给予最高50万元、30万元支持。 5.支持医疗器械研发和转化。对进入国家和上海市创新医疗器械特别审查程序的产品，按照不超过产品研发费用的30%，分别给予最高200万元、100万元支持;以上产品首次取得注册证并落地生产的，给予最高400万元支持。 对具有自主知识产权并取得其他第二类(不含第二类诊断试剂及设备零部件)、第三类医疗器械注册证并落地生产的，按照不超过产品研发费用的20%，分别给予最高50万元、100万元支持。对实现进口替代的二、三类医疗器械，追加给予最高100万元支持。 6.支持产学研医合作研发。鼓励企业与高校、科研院所、医疗机构等联合开展关键技术研发攻关和科技成果落地转化，给予最高200万元支持。 7.支持仿制药和原料药获批。对获得国家药监局批件的仿制药、生物类似药，按照不超过产品研发费用的20%，给予最高100万元支持，其中给予首仿药最高300万元支持，对首仿药对标原研药通过相关国际认证，再给予最高50万元支持。 支持原料药及关键中间体研发与产业化，对具有自主知识产权或突破性工艺并投产的高端原料药及高附加值医药中间体，按照不超过产品研发费用的20%，给予最高100万元支持。 8.支持产业专业化认证。对通过国家新版药物非临床研究质量管理规范(GLP)、药物(含医疗器械)临床试验质量管理规范(GCP)等资格认证的单位给予支持，给予最高50万元支持，每新增一个备案专业且开展业务的，给予最高5万元支持。 对取得国家级、市级医疗机构执业许可证的第三方医学实验室，分别给予最高50万元、30万元支持。 (三)支持扩大规模 9.支持创新产品示范应用与推广。支持企业与医疗机构合作开展创新药械应用示范项目，进行上市后评价、真实世界疗效评价、适应症拓展等研究，给予每个项目最高100万元支持。支持临床应用场景开发，按照不超过当年采购额的3%，给予最高100万元支持。 10.支持委托研发生产。支持承接研发生产活动(委托双方需无投资关联关系)，按照不超过每个受托品种(具备相应的药品、医疗器械生产批件)首次合同执行额的5%，分别给予最高各200万元支持。支持研发服务机构(CRO等)发展，按照不超过年度实际服务金额的5%，给予最高100万元支持。 对合同研发生产组织(CDMO)、合同生产组织(CMO)和生产企业承接药品上市许可持有人、医疗器械注册人委托生产活动的(委托双方无投资关联关系)，给予受托方不超过受托年生产产值的5%，最高100万元支持。 11.鼓励企业打造拳头产品。对单一药品或医疗器械产品，对销售额达到一定标准的企业，给予最高300万元支持。 12.支持开拓海外市场。对企业研发的创新药和医疗器械，新获得相关国际权威认证，并在相关国外市场实现销售的药品和医疗器械，分别给予最高200万元、100万元支持。 鼓励创新型企业与跨国企业对接合作，对于首付款5000万元以上的海外权益许可交易(双方须无投资关联关系)，按照出让企业实际交易金额的20%或对其第三方等专业服务投入的20%，给予最高200万元支持。 三、项目申报和评审 (一)本办法按操作细则实施。符合条件的单位按照细则要求，提供相关证明材料。项目申报单位应对申报材料的真实性负责。 (二)区科委对相关申报项目开展评审，必要时邀请第三方机构参与评审，对涉及按核定金额支持的项目视需要委托审计机构进行专项审计。 (三)项目承担单位应当严格执行财政资金管理的有关规定对虚报、瞒报骗取扶持资金或不按规定用途使用扶持资金的行为，将追究有关责任。 (四)本办法中涉及的政策扶持资金来源为奉贤区财政专项资金。扶持资金由区、街镇(开发区及国企)按财力结算比例分别承担。 四、附则 (一)对符合本政策规定的同一项目、同一事项，同时符合奉贤区其他扶持政策规定(含市级部门要求奉贤区配套或负担资金的政策规定)，按照“从优、就高、不重复”的原则予以支持，且单个企业当年度累计支持金额最高6000万元。对非共识及特别优质项目，经区相关产业专班提出意见，由分管领导提请区政府专题会或区政府常务会审定(与本政策其他条款不重复享受)，资金由区财政全额承担。 (二)本政策由奉贤区科学技术委员会负责解释。2025年1月1日至本政策发布前符合《奉贤区促进生命健康产业高质量发展若干政策》(沪奉府规〔2023〕1号)支持内容的，参照本政策执行。 (三)本政策自发布之日起实施，有效期至2027年12月31日。实施期间如遇国家级、市、区级有关政策及规定调整的，可进行相应调整。